Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Sanuwave Health Q3 2026 Results: Net Loss of $1.42M

SANUWAVE Health reported a net operating loss of $2.5 million for the nine months ended September 30, 2026, compared to an operating income of $2.9 million in the prior year period. Total revenue decreased to $27.9 million from $30.7 million, while operating expenses increased primarily due to higher research and development and selling costs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue8.611.3
Gross profit6.68.7
Profit before tax-1.49.7
Net income-1.49.7
EPS (diluted, $ a share)$-0.16$0.39

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year-23.9%
Gross margin77.3%
Operating margin-12.5%
Source

10-Q filed with the SEC, NASDAQ: SNWV. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Sanuwave Health, Inc.: key numbers

Share price
$1.81Close, Nov 16
Market cap
$15.6M
Shares outstanding
8.6MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Sanuwave Health, Inc.

All →
5:09 PM ET 8-K
Financial Results

Sanuwave Health Financial Results

SANUWAVE Health reported Q3 2026 revenue of $8.6 million, a 24% decrease year-over-year, primarily driven by a significant drop in Ultramist system sales. The company posted a net loss of $1.4 million for the quarter, compared to net income of $9.7 million in the prior year, which had benefited from one-time gains. Management attributed the performance to market uncertainty surrounding proposed CMS rule changes affecting wound care reimbursement.

Term
Q3 2026

“Q3 was very much the story of the CMS proposed rule. This affected Sanuwave in multiple ways. The proposal to maintain skin substitute pricing at 2026 levels for 2027 caused a number of mobile wound care practitioners, particularly those providing rural home care, to exit some or all of their operations.”

Morgan Frank, CEO
5:16 PM ET 8-K
Loan & Debt

Sanuwave Health Debt Financing Update with JPMorgan Chase Bank, N.A.

SANUWAVE Health entered into an amendment and waiver to its existing credit agreement with JPMorgan Chase Bank. The lenders waived a default related to the fixed charge coverage ratio for the period ending September 30, 2026, while tightening restrictions on acquisitions, stock repurchases, and permitted indebtedness.

Counterparty
JPMorgan Chase Bank, N.A.
4:39 PM ET 8-K
Nasdaq/NYSE Compliance Notice

Sanuwave Health Nasdaq/NYSE Compliance Notice

SANUWAVE Health received a deficiency notice from Nasdaq because its Market Value of Listed Securities (MVLS) fell below the $50 million minimum requirement for 30 consecutive business days. The company has 180 calendar days, or until March 22, 2027, to regain compliance by maintaining an MVLS of at least $50 million for 10 consecutive business days.

Counterparty
Nasdaq
Term
180 days

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.